Sarepta Therapeutics Names Sandy Mahatme Senior Vice President, CFO
Sarepta Therapeutics(NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced the appointment of Sandesh "Sandy" Mahatme, senior vice president, chief financial officer, and David Tyronne "Ty" Howton, senior vice president, general counsel, effective today.
"Both Sandy and Ty bring a considerable breadth of experience to Sarepta gained from their senior roles at industry-leading biotechs," said Chris Garabedian, Sarepta's president and CEO. "They provide tremendous strength to Sarepta's executive team in dealing with the financial, legal, and corporate development activities associated with a growth biotech company as we bring eteplirsen through late-stage development and commercialization."
Mr. Mahatme joins Sarepta from Celgene Corporation where he served in various roles including senior vice president of Corporate Development, Corporate Treasurer and senior vice president of Tax since 2006. While at Celgene, Mr. Mahatme was instrumental in building Celgene's Treasury and Tax functions before establishing the Corporate Development department, focused on strategic, targeted initiatives including emerging markets, acquisitions and licensing and strategic planning. Prior to Celgene, Mr. Mahatme worked for Pfizer Inc. for eight and a half years in senior roles in Business Development and Corporate Tax. Mr. Mahatme started his career at Ernst & Young where he advised multinational corporations on a broad range of transactions. Mr. Mahatme holds Master of Laws (LL.M) degrees from Cornell Law School and NYU School of Law and is a member of the New York State Bar Association.
Mr. Mahatme commented, "Sarepta has great potential to build a successful independent biotech company on the strength of eteplirsen for Duchenne muscular dystrophy and I will be focused on ensuring that the company is well positioned financially to advance the program forward."
Mr. Howton joins Sarepta from Vertex Pharmaceuticals where he was the senior vice president, chief legal officer and a member of the executive team. In that capacity, Mr. Howton participated in the general management of the company and oversaw all aspects of the Vertex global legal and compliance departments. Prior to his appointment as chief legal officer in 2011, Mr. Howton served as the chief compliance officer and was responsible for designing and implementing the Vertex corporate compliance program as well as chairing the company's Corporate Compliance Committee. Mr. Howton joined Vertex in 2009 from Genentech where he served in a number of legal roles before becoming the company's chief healthcare compliance officer. Prior to joining Genentech Inc. in 2003, Mr. Howton was a member of the Sidley Austin LLP corporate healthcare practice where he advised on corporate transactions involving life science companies and provided regulatory counsel. Mr. Howton holds a B.A. from Yale University and a J.D. from Northwestern University School of Law.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.